Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11304960 | VERITY | Steroidal compositions |
Jan, 2029
(4 years from now) | |
US8778922 | VERITY | Steroidal compositions |
Jan, 2029
(4 years from now) | |
US8865695 | VERITY | Steroidal compositions |
Jan, 2029
(4 years from now) | |
US11433083 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
US11311555 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
US11364249 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
US9949985 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
US10716794 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
US10226473 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
US9943527 | VERITY | High-strength testosterone undecanoate compositions |
Nov, 2030
(6 years from now) | |
US11559530 | VERITY | Oral testosterone undecanoate therapy |
Nov, 2037
(13 years from now) | |
US11464735 | VERITY | Fixed dose oral testosterone undecanoate compositions and use thereof |
Apr, 2041
(16 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5776885 | VERITY | Sustained and controlled release of water insoluble polypeptides |
Jul, 2015
(8 years ago) | |
US10166181 | VERITY | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(5 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Mar 10, 2013 |
Drugs and Companies using TRIPTORELIN PAMOATE ingredient
Market Authorisation Date: 10 March, 2010
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR